

PROVINCIAL FUNDING SUMMARY

Gemtuzumab Ozogamicin (Mylotarg) for Acute Myeloid Leukemia (pCODR 10190)

pERC Recommendation: Reimburse

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: April 20, 2020

This information is current as of October 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under provincial consideration		
AB	Under provincial consideration		
SK	Under provincial consideration		
MB	Funded		<ul style="list-style-type: none"> • In combination with daunorubicin and cytarabine for the treatment of adult patients with previously, untreated, de novo CD33-positive acute myeloid leukemia, except acute promyelocytic leukemia (APL). • Eligible patients include adults with previously untreated, de novo CD33-positive AML, except APL, who have good performance status and favourable, intermediate or unknown cytogenetics* (using the European LeukemiaNet [ELN] 2017 risk classification). Should a patient's unknown cytogenetic status become known as adverse, then gemtuzumab ozogamicin is discontinued. *unknown cytogenetics because the test was unsuccessful or because cytogenetic results are not yet available <p>Note: Gemtuzumab ozogamicin in combination with daunorubicin** and cytarabine should consist of one induction cycle; if a second induction cycle is required, gemtuzumab ozogamicin should not be administered during the second induction cycle. For patients with complete remission following induction, gemtuzumab ozogamicin in combination with standard cytarabine consolidation*** or cytarabine and daunorubicin consolidation for up to 2 cycles is permitted. **idarubicin can also be used ***standard cytarabine consolidation also known as single agent high dose cytarabine</p>

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Under provincial consideration		
NS	Under provincial consideration		
NB	Under provincial consideration		
NL	Under provincial consideration		
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.